Neumora Therapeutics, Inc. (NMRA)
NASDAQ: NMRA · Real-Time Price · USD
1.930
+0.010 (0.52%)
At close: Jan 31, 2025, 4:00 PM
1.902
-0.028 (-1.45%)
After-hours: Jan 31, 2025, 6:59 PM EST
Neumora Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
124
Market Cap
311.81M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 63.17B |
AbbVie | 56.33B |
Novartis AG | 51.72B |
AstraZeneca | 51.21B |
Thermo Fisher Scientific | 42.88B |
Abbott Laboratories | 41.95B |
NMRA News
- 4 weeks ago - Neumora Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - NMRA - Business Wire
- 4 weeks ago - Neumora Therapeutics Stock Tanks as Its Depression Drug Misses Goals - Investopedia
- 4 weeks ago - Neumora Therapeutics' stock craters after trial of major depressive disorder fails to meet main goals - Market Watch
- 4 weeks ago - Neumora Therapeutics' depression drug fails to meet main goal of late-stage study - Reuters
- 4 weeks ago - Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder - GlobeNewsWire
- 5 weeks ago - Neumora: Koastal-1 Readout For MDD Treatment Is First Study On Deck - Seeking Alpha
- 2 months ago - This biotech's stock could double if its treatment for major depressive disorder succeeds, says Mizuho - Market Watch
- 2 months ago - Neumora Therapeutics, Inc. (NMRA) Q3 2024 Earnings Call Transcript - Seeking Alpha